Tafamidis treatment in transthyretin cardiac amyloidosis: A retrospective cohort analysis of outcomes and associated factors - 07/02/26
, Sylvain Aguilhon a, Quentin Delbaere a, Audrey Agullo a, Caroline Padovani a, Valentin Dupasquier a, Christophe Hédon a, b, Valentin Femenia a, c, Nawel Aouni a, Florence Leclercq a, Jean-Luc Pasquie a, b, Joana Pissarra d, Lionel Moulis d, Nicolas Chapet e, François Roubille aGraphical abstract |
Highlights |
• | The analysed cohort included 128 patients with ATTR-CM under tafamidis treatment. |
• | This cohort provides a comprehensive representation of our health region. |
• | The cohort also provides data from a real-life setting. |
• | In all, 33% reached the composite cardiovascular endpoint (death or hospitalization). |
• | NYHA stage decreased significantly in the year following treatment. |
• | NT-proBNP > 1000 ng/L at diagnosis was a major risk factor for death or admission. |
Abstract |
Background |
Transthyretin cardiac amyloidosis is an important cause of heart failure. Tafamidis, the only specific treatment for cardiac amyloidosis currently widely available in France, has been shown to reduce mortality efficiently.
Aim |
The purpose of this study was to describe time to cardiovascular events (death or hospitalization) in patients with transthyretin cardiac amyloidosis treated with tafamidis, and to investigate associated factors.
Methods |
We retrospectively included consecutive patients with a new diagnosis of transthyretin cardiac amyloidosis and an indication for tafamidis in a tertiary centre from August 2012 to July 2022. We collected time-to-event data, and associated clinical, biological, ultrasound and therapeutic factors.
Results |
We included 128 patients, with visits every 6 months and a median follow-up of 15 months. A total of 42 patients (33%) died or were hospitalized for cardiovascular causes, with a median time-to-event of 1050 days (95% confidence interval 897 – not available). The mean time between diagnosis and start of treatment was 127 ± 361 days. Several factors were associated with cardiovascular outcomes: older age at diagnosis correlated with reduced frequency of death or hospitalization (hazard ratio 0.93, 95% confidence interval 0.89-0.97; P < 0.01), whereas obesity correlated with increased occurrence of death or hospitalization (hazard ratio 3.95, 95% confidence interval 1.45-10.76; P = 0.01). More importantly, N-terminal prohormone of B-type natriuretic peptide > 1000 ng/L at diagnosis was a major risk factor in the multivariable analysis (hazard ratio 4.10, 95% confidence interval 1.64-10.25; P < 0.01). After the initiation of treatment, New York Heart Association class and weight decreased significantly.
Conclusions |
Patients with transthyretin cardiac amyloidosis have a poor prognosis in the short term, despite the use of tafamidis. Important prognostic factors, including clinical features and biomarkers (especially N-terminal prohormone of B-type natriuretic peptide) are essential for risk stratification. As these surrogate endpoints show significant improvement after starting tafamidis, initiating therapy promptly appears mandatory in the most severe patients.
Le texte complet de cet article est disponible en PDF.Keywords : Amyloidosis, Tafamidis, Death, Prognosis, Prohormone of brain natriuretic peptide (1–76)
Plan
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?